UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Ioannou Y, Isenberg DA
  • Publication date:
    10/2002
  • Pagination:
    599, 606
  • Journal:
    Postgraduate Medical Journal
  • Volume:
    78
  • Issue:
    924
  • Print ISSN:
    0032-5473
  • Keywords:
    adherence, adrenal, Adrenal Cortex Hormones, adult, ADULTS, age, AGENT, AGENTS, Algorithms, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Antimalarials, Antineoplastic Agents, Antiphospholipid Syndrome, As, autoimmune, Azathioprine, biotechnology, CHALLENGE, Chronic, Class, clinical, CLINICAL PRESENTATION, COMBINATION, cortex, corticosteroid, CORTICOSTEROIDS, Cyclophosphamide, Damage, development, diet, diet therapy, disease, DRUG, drug therapy, DRUGS, effects, FAT, Female, fish, fish oil, hormone, Hormones, IM, IMMUNOGLOBULIN, IMMUNOGLOBULINS, Immunoglobulins, Intravenous, Immunosuppressive Agent, Immunosuppressive Agents, Inflammation, INTRAVENOUS, INVOLVEMENT, LA, Low, Lupus, Lupus Erythematosus, Systemic, Management, May, Methods, NEED, oil, Patient, patients, Pharmacological, plasma exchange, Pregnancy, Pregnancy Complications, PROTECTION, Review, rheumatic disease, side effect, side effects, SLE, Smoking, smoking cessation, stress, SYMPTOM, SYMPTOMS, SYSTEMIC, SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC-LUPUS-ERYTHEMATOSUS, therapeutic, therapeutic use, THERAPIES, therapy, Use, Vaccination, WOMEN
  • Notes:
    UI - 22302897 DA - 20021104 IS - 0032-5473 LA - eng PT - Journal Article PT - Review PT - Review, Tutorial RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Antimalarials) RN - 0 (Antineoplastic Agents) RN - 0 (Immunoglobulins, Intravenous) SB - IM
Abstract
Systemic lupus erythematosus (SLE) is a chronic, autoimmune rheumatic disease with many clinical presentations typically affecting women of childbearing age. The successful therapy of SLE depends upon treating both symptoms and the underlying inflammation. Both non-pharmacological as well as pharmacological therapies are invariably required. Non-pharmacological therapy includes avoiding over-exposure to sunlight with the use of adequate sunscreen protection, avoiding "live" vaccination if on immunosuppressive agents, adherence to a diet low in saturated fat and high in fish oil, stress avoidance, and smoking cessation. Pharmacological measures revolve around four main classes of drugs: non-steroidal anti-inflammatory drugs, antimalarials, corticosteroids, and cytotoxic agents. Cyclophosphamide and azathioprine are the two most commonly used cytotoxic agents and these in combination with corticosteroids need to be employed early if there is major organ involvement to prevent or minimise irreversible damage. The potential side effects of corticosteroids and cytotoxic agents need constant consideration. The rapid developments in biotechnology of recent years may soon lead to new and more specific therapies for patients with SLE
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Div of Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by